[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554084":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":66,"collaborators":68,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":41,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":41,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":50,"whyStopped":41,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"The Miriam Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DHA group","EXPERIMENTAL","Participants will receive DHA supplement. 3 gelcaps, three times per day with meals (breakfast, lunch, and dinner). DHA supplement regimen contains 450 mg DHA and minimal EPA (60 mg) per pill.\n\nParticipants will be given 28-day food and activity log.",[13],"Drug: DHA",{"label":15,"type":10,"description":16,"interventionNames":17},"EPA group","Participants will receive EPA supplement. 2 gelcaps, two times per day with meals (breakfast and dinner). 1 gelcap consists of 1 gram of EPA.\n\nParticipants will be given 28-day food and activity log.",[18],"Drug: EPA",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","EPA","Fish oil",[15],[26],"eicosapentaenoic acid",{"type":21,"name":28,"description":23,"armGroupLabels":29,"otherNames":30},"DHA",[9],[31],"docosahexaenoic Acid",[33],{"name":34,"affiliation":35,"role":36},"Wenliang Song, MD","LIFESPAN CARDIOVASCULAR INSTITUTE","PRINCIPAL_INVESTIGATOR",[38,43],{"name":34,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","4014449851",null,"WSong@Lifespan.org",{"name":44,"role":39,"phone":45,"phoneExt":41,"email":46},"Daria Salamevich","4014449857","DSalamevich@Lifespan.org",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Brown University Health - Lipid Clinic","RECRUITING","Providence","Rhode Island","02914","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-71.41283,41.82399,{"lat":60,"lon":59},[63],{"name":34,"role":39,"phone":64,"phoneExt":41,"email":65},"267 951 77 59","wsong@brownhealth.org",{"type":67,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[69,72],{"name":70,"class":71},"National Institutes of Health (NIH)","NIH",{"name":73,"class":71},"National Heart, Lung, and Blood Institute (NHLBI)","100554084","early-phase-1-differential-thrombogenesis-by-epa-and-dha-mediated-by-hdl-100554084",false,"NCT06494488","Differential Thrombogenesis by EPA and DHA Mediated by HDL","Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL)","Inclusion Criteria:\n\n* Fasting TG levels ≥ 150 mg\u002FdL and \\\u003C 500 mg\u002FdL and HDL-C ≤ 40 (men) or ≤ 50 (women)\n* LDL-C \\> 40 mg\u002FdL and ≤ 130 mg\u002FdL\n* Able to provide informed consent and adhere to study schedules\n* Agree to follow and maintain a relatively stable and low fatty fish intake diet (\\\u003C3 servings per week)\n\nExclusion Criteria:\n\n* Female with pregnancy, planned pregnancy (within the study period), or currently breastfeeding.\n* Subjects with weight changes greater than 20% over the past 3 months\n* Subjects planning a significant change in diet or exercise levels\n* Malabsorption syndrome and\u002For chronic diarrhea\n* Use of dietary supplements containing n-3 PUFA fatty acids\n* Frequent consumption of n-3 PUFA-enriched fish (\\>3 times a week)\n* Abnormal liver, kidney, or thyroid functions\n* Drug or alcohol abuse within 6 months or significant mental\u002Fpsychological impairment\n* Current smokers\n* Subjects taking daily aspirin, NSAIDs, anticoagulant, or corticosteroids\n* Subjects with known bleeding disorders (for example, hemophilia)\n* Known sensitivity or allergy to fish, shellfish, or omega-3 fatty acid supplements\n* Subjects requiring regular transfusions for any reason\n* No ethnic\u002Fracial groups will be excluded","ALL","18 Years","69 Years",{"count":85,"type":86},80,"ESTIMATED","INTERVENTIONAL",[89],"EARLY_PHASE1","The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.\n\nThe purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\nParticipants will:\n\nVisit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.",[92,93],"Lipid Metabolism Disorders","Hypertriglyceridemia",[23,95,96],"Atherogenic lipidemia","Lipoproteins","2025-09-25",{"date":99,"type":100},"2025-10-01","ACTUAL",{"date":102,"type":100},"2025-07-10",{"date":104,"type":86},"2028-03-31",{"name":5,"class":6},1]